The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Andreeva T.A.

City Polyclinic No. 37, St. Petersburg, Russia;
City Hemophilia Treatment Center, St. Petersburg, Russia

Zharkov P.A.

Dmitry Rogachev Federal Research-and-Clinical Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia

Zozulya N.I.

National Research Center for Hematology

Zorenko V.Yu.

National Medical Research Center for Hematology

Konstantinova V.N.

City Polyclinic No. 37, St. Petersburg, Russia;
City Hemophilia Treatment Center, St. Petersburg, Russia

Lavrentieva I.N.

Morozovsky Children's City Clinical Hospital of the Moscow City Health Department

Davydkin I.L.

Samara State Medical University

Petrov V.Yu.

Morozovsky Children's City Clinical Hospital of the Moscow City Health Department

Polyanskaya T.Yu.

National Research Center for Hematology

Soldatenkov V.E.

Russian Research Institute of Hematology and Transfusion Medicine

Shutov S.A.

National Research Center for Hematology

Methodological recommendations for surgical care in patients with hemophilia A receiving prophylactic therapy with emicizumab

Authors:

Andreeva T.A., Zharkov P.A., Zozulya N.I., Zorenko V.Yu., Konstantinova V.N., Lavrentieva I.N., Davydkin I.L., Petrov V.Yu., Polyanskaya T.Yu., Soldatenkov V.E., Shutov S.A.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2024;(3‑2): 3‑20

DOI: 10.17116/hirurgia20240323

Read: 2288 times

Download PDF (RU)
Contact the author
Table of contents

METHODOLOGICAL RECOMMENDATIONS FOR SURGICAL CARE IN PATIENTS WITH HEMOPHILIA A RECEIVING PROPHYLACTIC THERAPY WITH EMICIZUMAB
METHODOLOGICAL RECOMMENDATIONS FOR SURGICAL CARE IN PATIENTS WITH HEMOPHILIA A RECEIVING PROPHYLACTIC THERAPY WITH EMICIZUMAB

To cite this article:

Andreeva TA, Zharkov PA, Zozulya NI, et al. . Methodological recommendations for surgical care in patients with hemophilia A receiving prophylactic therapy with emicizumab. Pirogov Russian Journal of Surgery. 2024;(3‑2):3‑20. (In Russ.)
https://doi.org/10.17116/hirurgia20240323

Подписка 2026 Хирургия. Журнал им. Н.И. Пирогова (Pirogov Russian Journal of Surgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Methodological recommendations for surgical care in patients with hemophilia A receiving prophylactic therapy with emicizumab. Recommendations of the expert group. Moscow, 2024.

Authors:

Andreeva T.A.

City Polyclinic No. 37, St. Petersburg, Russia;
City Hemophilia Treatment Center, St. Petersburg, Russia

Zharkov P.A.

Dmitry Rogachev Federal Research-and-Clinical Center for Pediatric Hematology, Oncology, and Immunology, Moscow, Russia

Zozulya N.I.

National Research Center for Hematology

Zorenko V.Yu.

National Medical Research Center for Hematology

Konstantinova V.N.

City Polyclinic No. 37, St. Petersburg, Russia;
City Hemophilia Treatment Center, St. Petersburg, Russia

Lavrentieva I.N.

Morozovsky Children's City Clinical Hospital of the Moscow City Health Department

Davydkin I.L.

Samara State Medical University

Petrov V.Yu.

Morozovsky Children's City Clinical Hospital of the Moscow City Health Department

Polyanskaya T.Yu.

National Research Center for Hematology

Soldatenkov V.E.

Russian Research Institute of Hematology and Transfusion Medicine

Shutov S.A.

National Research Center for Hematology

Close metadata

References:

  1. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, Carcao M, Mahlangu J, Ragni MV, Windyga J, Llinás A, Goddard NJ, Mohan R, Poonnoose PM, Feldman BM, Lewis SZ, van den Berg HM, Pierce GF; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158.  https://doi.org/10.1111/hae.14046
  2. Kruse-Jarres R, Peyvandi F, Oldenburg J, Chang T, Chebon S, Doral MY, Croteau SE, Lambert T, Kempton CL, Pipe SW, Ko RH, Trzaskoma B, Dhalluin C, Bienz NS, Niggli M, Lehle M, Paz-Priel I, Young G, Jiménez-Yuste V. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Advances. 2022;6(24):6140-6150. https://doi.org/10.1182/bloodadvances.2022007458
  3. Castaman G, Santagostino E, Kremer Hovinga J, Schutgens R, Robson S, Meier O, Jiménez-Yuste V. Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A (PwHA) with FVIII Inhibitors: Data from the Second Interim Analysis [abstract]. Res Pract Thromb Haemost. 2020;4(suppl 1).
  4. Buckner TW, Carpenter SL, Daoud N, Lattimore SU, Lee L, McLean T, Morton P, Recht M. Surgeries and procedures in people with haemophilia A on emicizumab prophylaxis: analysis from the ATHN 7 haemophilia natural history study. The European Association for Haemophilia and Allied Disorders (EAHAD) Annual Meeting. 2023;PO166.
  5. McCary I, Guelcher C, Kuhn J, Butler R, Massey G, Guerrera MF, Ballester L, Raffini L. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures. Haemophilia. 2020;26(4):631-636.  https://doi.org/10.1111/hae.14005
  6. Biron-Andreani C, Diaz-Cau I, Ranc A, Navarro R, Leonardi C, Dischino M, Guy R, Theron A, Garcia-Gournay C, Santagostino E, Schved JF. Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring. Br J Haematol. 2020;189(3):e100-e103. https://doi.org/10.1111/bjh.16512
  7. Isaacs J, Welsby IJ, Schroder JN, Onwuemene OA. Activated Coagulation Time and Hepcon Protamine Titration Device to Manage Unfractionated Heparin During Cardiopulmonary Bypass in a Hemophilia A Patient on Emicizumab. J Cardiothorac Vasc Anesth. 2021;35(11):3299-3302. https://doi.org/10.1053/j.jvca.2020.08.058
  8. Barg AA, Avishai E, Budnik I, Levy-Mendelovich S, Barazani TB, Kenet G, Livnat T. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort. Pediatr Blood Cancer. 2019;66(11):e27886. https://doi.org/10.1002/pbc.27886
  9. Escobar M, Dunn A, Quon D, Trzaskoma B, Lee L, Ko RH, Carpenter SL. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures. Haemophilia. 2022;28(4):e105-e108. https://doi.org/10.1111/hae.14574
  10. Evans MS, Davis C, Eyster ME. Total knee replacement with and without emicizumab: a unique comparison of perioperative management. Blood Adv. 2020;4(5):855-857.  https://doi.org/10.1182/bloodadvances.2019001060
  11. Lewandowska M, Randall N, Bakeer N, Maahs J, Sagar J, Greist A, Shapiro AD. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US. Haemophilia. 2021;27(1):90-99.  https://doi.org/10.1111/hae.14212
  12. Seaman CD, Ragni MV. Emicizumab use in major orthopedic surgery. Blood Adv. 2019;3(11):1722-1724. https://doi.org/10.1182/bloodadvances.2019000228
  13. Cohen O, Levy-Mendelovich S, Budnik I, Ludan N, Lyskov SK, Livnat T, Avishai E, Efros O, Lubetsky A, Lalezari S, Misgav M, Brutman-Barazani T, Kenet G, Barg AA. Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center. Res Pract Thromb Haemost. 2023;7(6):102178. https://doi.org/10.1016/j.rpth.2023.102178
  14. Castaman G, Linari S, Pieri L, Carulli C, Prosperi P, Tonelli P, Demartis F, Fjerza R, Attanasio M, Coppo M, Salvianti F. Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience. J Clin Med. 2023;12(6):2317. https://doi.org/10.3390/jcm12062317
  15. Jiménez-Yuste V, Rodríguez-Merchán EC, Matsushita T, Holme PA. Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery. Haemophilia. 2021;27(4):519-530.  https://doi.org/10.1111/hae.14322
  16. https://doi.org/10.25760/VA-2018-92-59-72 
  17. Susen S, Gruel Y, Godier A, Harroche A, Chambost H, Lasne D, Rauch A, Roullet S, Fontana P, Goudemand J, de Maistre E, Chamouard V, Wibaut B, Albaladejo P, Négrier C. Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra® ): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP). Haemophilia. 2019;25(5):731-737.  https://doi.org/10.1111/hae.13817
  18. Coppola A, Castaman G, Santoro RC, Mancuso ME, Franchini M, Marino R, Rivolta GF, Santoro C, Zanon E, Sciacovelli L, Manca S, Lubrano R, Golato M, Tripodi A, Rocino A; ad hoc Working Group. Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Haemophilia. 2020;26(6):937-945.  https://doi.org/10.1111/hae.14172
  19. MASAC Document 258 — Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra) for Hemophilia A with and without Inhibitors. https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-258-recommendation-on-the-use-and-management-of-emicizumab-kxwh-hemlibrar-for-hemophilia-a-with-and-without-inhibitors
  20. Schild FJ, Mauser-Bunschoten EP, Verbout AJ, Van Rinsum AC, Roosendaal G. Total knee arthroplasty in hemophilic arthropathy: efficiency of clotting factor usage in multijoint procedures. J Thromb Haemost. 2009;7(10):1741-1743. https://doi.org/10.1111/j.1538-7836.2009.03569.x
  21. Schutgens REG, Jimenez-Yuste V, Escobar M, Falanga A, Gigante B, Klamroth R, Lassila R, Leebeek FWG, Makris M, Owaidah T, Sholzberg M, Tiede A, Werring DJ, van der Worp HB, Windyga J, Castaman G. Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance. Hemasphere. 2023;7(6):e900. https://doi.org/10.1097/HS9.0000000000000900
  22. Шутов С.А. Стратегия хирургической помощи больным гемофилией: Дис. ... мед. наук. М. 2015.
  23. Общая характеристика лекарственного препарата эмицизумаб — для медицинских специалистов от 23.06.2023. Регистрационный номер ЛП-№ (001088)-(РГ-RU).
  24. Adamkewicz JI, Chen DC, Paz-Priel I. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays. Thromb Haemost. 2019;119(7):1084-1093. https://doi.org/10.1055/s-0039-1688687
  25. Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A. Thromb Haemost. 2019;119(9):1384-1393. https://doi.org/10.1055/s-0039-1692427
  26. Choi S, Brull R. Neuraxial techniques in obstetric and non-obstetric patients with common bleeding diatheses. Anesth Analg. 2009;109(2):648-660.  https://doi.org/10.1213/ane.0b013e3181ac13d1
  27. https://www.rlsnet.ru/drugs/traneksam-29530#sposob-primeneniia-i-dozy
  28. López-Jaime FJ, Benítez O, Díaz Jordán BL, Montaño A, Coll J, Quintana París L, Gómez-Del Castillo Solano MDC. Expert opinion paper on the treatment of hemophilia a with emicizumab. Hematology. 2023;28(1):2166334. https://doi.org/10.1080/16078454.2023.2166334
  29. Santagostino E, Oldenburg J, Chang T, Chebon S, Doral M, Jimenez Yuste V, Liesner R, Croteau S, Lambert T, Kempton C, Pipe S, Dhalluin C, Bienz NS, Vignal C, Lehle M, Young G, Kruse-Jarres R. Surgical experience from four phase III studies (HAVEN 1-4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors. Res Pr Thromb Haemost. 2019;3(supp 3):115. 
  30. Escuriola-Ettingshausen C, Auerswald G, Königs C, Kurnik K, Scholz U, Klamroth R, Oldenburg J. Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel. Haemophilia. 2021;27(3):e305-e313. https://doi.org/10.1111/hae.14010
  31. Collins PW, Liesner R, Makris M, Talks K, Chowdary P, Chalmers E, Hall G, Riddell A, Percy CL, Hay CR, Hart DP. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia. 2018;24(3):344-347.  https://doi.org/10.1111/hae.13495
  32. Collins PW, Quon DVK, Makris M, Chowdary P, Kempton CL, Apte SJ, Ramanan MV, Hay CRM, Drobic B, Hua Y, Babinchak TJ, Gomperts ED. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia. 2018;24(1):104-112.  https://doi.org/10.1111/hae.13324
  33. https://www.rlsnet.ru/drugs/feiba-35265#vzaimodeistvie
  34. Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017;377(9):809-818.  https://doi.org/10.1056/NEJMoa1703068
  35. Hartmann R, Feenstra T, Valentino L, Dockal M, Scheiflinger F. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. J Thromb Haemost. 2018. Epub ahead of print. https://doi.org/10.1111/jth.14203
  36. Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Negrier C. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica. 2018;103(4):e181-e183. https://doi.org/10.3324/haematol.2017.185330
  37. MASAC document 268 — recommendation on the use and management of emicizumab-kxwh (Hemlibra) for hemophilia A with and without inhibitors. https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-268-recommendation-on-the-use-and-management-of-emicizumab-kxwh-hemlibrar-for-hemophilia-a-with-and-without-inhibitors
  38. Hermans C, Altisent C, Batorova A, Chambost H, De Moerloose P, Karafoulidou A, Klamroth R, Richards M, White B, Dolan G; European Haemophilia Therapy Standardisation Board. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia. 2009;15(3):639-658.  https://doi.org/10.1111/j.1365-2516.2008.01950.x
  39. Kavakli K. Fibrin glue and clinical impact on haemophilia care. Haemophilia. 1999;5(6):392-396.  https://doi.org/10.1046/j.1365-2516.1999.00348.x
  40. Serban M, Poenaru D, Pop L, Ionita H, Mihailov MD, Tepeneu N, Bădeţi R, Lighezan D, Schramm W. Surgery — a challenge in haemophiliacs with inhibitors. Hamostaseologie. 2009;29(suppl 1):S39-41. 
  41. Poston JN, Kruse-Jarres R. Perioperative hemostasis for patients with hemophilia. Hematology Am Soc Hematol Educ Program. 2022;2022(1):586-593.  https://doi.org/10.1182/hematology.2022000387
  42. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935-1939. https://doi.org/10.1111/jth.12672
  43. Carcao M, Gouider E, Wu R. Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia. Haemophilia. 2022;28(sSuppl 4):26-34.  https://doi.org/10.1111/hae.14552
  44. Cai J, Ribkoff J, Olson S, Raghunathan V, Al-Samkari H, DeLoughery TG, Shatzel JJ. The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. Eur J Haematol. 2020;104(2):79-87.  https://doi.org/10.1111/ejh.13348
  45. Castaman G, Santoro C, Coppola A, Mancuso ME, Santoro RC, Bernardini S, Pugliese FR, Lubrano R, Golato M, Tripodi A, Rocino A, Santagostino E; ad hoc Working Group; Biasoli C, Borchiellini A, Catalano A, Contino L, Coluccia A, Cultrera D, De Cristofaro R, Di Minno G, Fabbri A, Franchini M, Gamba G, Giuffrida AC, Gresele P, Giampaolo A, Hassan HJ, Luciani M, Marchesini E, Marino R, Mazzucconi MG, Molinari AC, Morfini M, Notarangelo LD, Peccarisi L, Peyvandi F, Pollio B, Rivolta GF, Ruggieri MP, Sargentini V, Schiavoni M, Sciacovelli L, Serino ML, Siragusa S, Tagliaferri A, Testa S, Tosetto A, Zampogna S, Zanon E. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfus. 2020;18(2):143-151.  https://doi.org/10.2450/2019.0186-19
  46. Hamid AAN, Smithson N. Dental extractions on a patient with severe haemophilia A and inhibitors taking emicizumab prophylaxis. A case report and review. Oral Surgery. 2022;15(4):592-596.  https://doi.org/10.1111/ors.12689
  47. Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lorenz C, Del Dot L, Ugolotti G, Dell’aringa C, Gandini G. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers. Haemophilia. 2005;11(5):504-509.  https://doi.org/10.1111/j.1365-2516.2005.01132.x
  48. Клинические рекомендации «Гемофилия». 2023 
  49. Kalsi H, Nanayakkara L, Pasi KJ, Bowles L, Hart DP. Access to primary dental care for patients with inherited bleeding disorders. Haemophilia. 2012;18(4):510-515.  https://doi.org/10.1111/j.1365-2516.2011.02716.x
  50. Jin P, Han Y, Tian F, Wang L, Zhao X, Zhang C, Xiao J. Electron-Rich Twistacene-Modified Arylboron Donor-Acceptor Systems: Synthesis, Photophysics, and Electroluminescence with Hot Exciton Response. Chemistry. 2020;26(14):3113-3118. https://doi.org/10.1002/chem.201904590
  51. Anderson JA, Brewer A, Creagh D, Hook S, Mainwaring J, McKernan A, Yee TT, Yeung CA. Guidance on the dental management of patients with haemophilia and congenital bleeding disorders. Br Dent J. 2013;215(10):497-504.  https://doi.org/10.1038/sj.bdj.2013.1097
  52. Champagne PA, Bourassa M, Desjardins MP, Cloutier S, Demers C, Singbo NU, Néron H, Pelland-Marcotte MC. Post-procedural bleeding rate and haemostatic treatment use for dental procedures before and after the implementation of a standardized protocol for people with inherited bleeding disorders. Haemophilia. 2022;28(5):806-813.  https://doi.org/10.1111/hae.14609
  53. Friedman M, White B, Dougall AJ. An audit of the protocol for the management of patients with hereditary bleeding disorders under-going dental treatment. J Disab Oral Health. 2009;10(4):151-155. 
  54. Coetzee MJ. The use of topical crushed tranexamic acid tablets to control bleeding after dental surgery and from skin ulcers in haemophilia. Haemophilia. 2007;13(4):443-444.  https://doi.org/10.1111/j.1365-2516.2007.01479.x
  55. Hewson I, Makhmalbaf P, Street A, McCarthy P, Walsh M. Dental surgery with minimal factor support in the inherited bleeding disorder population at the Alfred Hospital. Haemophilia. 2011;17(1):e185-188.  https://doi.org/10.1111/j.1365-2516.2010.02346.x
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.